Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Aticaprant for Relapse Prevention in MDD With Anhedonia
2024-511057-22-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Aticaprant + antidepressant with Placebo + antidepressant (2 arms). Primary endpoint: Time to relapse. Started Nov 2024; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-511057-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511057-22-00.